IL-6 presumably decreased the chemosensitivity of osteosarcoma cells to lobaplatin through estrogen, apoptosis or IL-17 signaling, and proteins involved in the above pathways, such as proto-oncogene, inositol 1,4,5-trisphosphate receptor type 1, keratin, type I cytoskeletal 17, and cytochrome c, may represent other potential targets for lobaplatin-resistant osteosarcoma. The gene discussed is CYCS; the disease is osteosarcoma.